SELECTIVE TRANSMISSION OF ANTIBODIES TO THE FETUS
选择性地将抗体传递给胎儿
基本信息
- 批准号:3456199
- 负责人:
- 金额:$ 10.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1993
- 资助国家:美国
- 起止时间:1993-04-01 至 1998-03-31
- 项目状态:已结题
- 来源:
- 关键词:affinity chromatography antibody receptor antibody specificity antigen antibody reaction antigen receptors autoradiography bactericidal immunity embryo /fetus enzyme linked immunosorbent assay immune complex immunity immunoglobulin G immunoglobulin structure laboratory mouse monoclonal antibody placental transfer radiotracer scintillation counter western blottings
项目摘要
One of the major neonatal defenses against bacterial and viral infection
is maternally-derived IgG. Low levels of transplacentally-acquired IgG
may be a contributing factor in the increased susceptibility of premature
neonates to infection. In addition to the transient protection afforded
by antibody against potentially infectious agents, passively acquired
anti-idiotypic antibody can alter the development of active immunity in
the neonate. In certain situations passively acquired antibody may not
be desirable. Antibody acquired in utero from diseased mothers may
interfere with early serodiagnosis of the disease in the neonate.
Passively acquired antibody from mothers with certain autoimmune diseases
not only hinder serodiagnosis but may also induce a transient form of the
disease in the neonate. The long term goal of the proposed study is to
establish more reliable methods for early serodiagnosis of disease in the
neonate and to develop strategies that will enhance neonatal resistance
to disease by regulating transplacental passage of selected antibody
specificities in utero. Proposed models of IgG transport to the fetus
involve binding to Fc receptors on placental tissues followed by
endocytosis of the receptor-ligand complex and transport across the cell
where IgG is released into the fetal circulation. Numerous studies
suggest that within an IgG subclass transport rates vary considerable
among different individuals and that within an individual there is
selective transfer of different antibody specificities. The hypothesis
to be tested in this proposal is that transport of antibody to the fetus
occurs by a mechanism that can preferentially select antibodies based on
their antigenic specificity or other idiotypic characteristics. This
mode of selection would be influenced by specific immune complexes that
exist during normal immune responses. To address this hypothesis
transport of monoclonal antibodies that have defined antigenic and
idiotypic specificities will be used. The specific aims of this proposal
are: 1) To determine what modification if any occurs to an IgG molecule
as it crosses the placenta; 2) To assess the effect of antigen/antibody
or idiotype/anti-idiotype immune complexes on the rate of transfer of a
monoclonal antibody across the placenta; and 3) To determine the effect
of maternal immune status on transplacental passage of antibodies. These
studies will provide insight into the mechanisms of transplacental
passage of antibodies, the identification of maternal antibody clonotypes
in fetal serum, and ways by which the maternal immune system might be
manipulated to enhance neonatal resistance to infection.
针对细菌和病毒感染的主要新生儿防御措施之一
是母体衍生的IgG。 低水平的移植获得IgG
可能是提高过早易感性的因素
新生儿感染。 除了提供瞬态保护
通过针对潜在感染剂的抗体,被动地获得
抗IDiotypic抗体可以改变主动免疫的发展
新生儿。 在某些情况下,被动获得的抗体可能不会
是理想的。 从患病母亲获得子宫内获得的抗体可能
干扰新生儿中疾病的早期血清诊断。
从患有某些自身免疫性疾病的母亲的被动获得的抗体
不仅会阻碍血清诊断,而且还可能引起瞬态形式
新生儿中的疾病。 拟议研究的长期目标是
建立更可靠的方法来早期疾病的早期诊断
新生儿并制定将增强新生儿抵抗力的策略
通过调节选定抗体的移植通过来疾病
子宫内的特异性。 提议的IgG转运到胎儿的模型
涉及与胎盘组织上的FC受体结合,然后
受体配体复合物的内吞作用和跨细胞的转运
IgG被释放到胎儿循环中。 许多研究
建议在IgG子类传输率中有所不同
在不同的个人中,一个人内部有
不同抗体特异性的选择性转移。 假设
在此提案中进行测试是抗体向胎儿的运输
通过一种可以优先选择基于基于的抗体的机制发生
它们的抗原特异性或其他白痴特征。 这
选择方式将受到特定免疫复合物的影响
在正常免疫反应中存在。 解决这一假设
已定义抗原和的单克隆抗体的运输
将使用白痴型特异性。 该提议的具体目的
是:1)确定如果发生在IgG分子的情况下发生什么修饰
当它越过胎盘时; 2)评估抗原/抗体的影响
或白痴型/抗IDiotype Anmune复合物的传递速率
胎盘上的单克隆抗体; 3)确定效果
母体免疫状态在抗体的移植通过。 这些
研究将提供有关移植机制的见解
抗体的通过,鉴定母体抗体clonotypes
在胎儿血清以及孕产妇免疫系统的方式中
操纵以增强新生儿对感染的抗性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KEITH ALAN KNISLEY其他文献
KEITH ALAN KNISLEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KEITH ALAN KNISLEY', 18)}}的其他基金
SELECTIVE TRANSMISSION OF ANTIBODIES TO THE FETUS
选择性地将抗体传递给胎儿
- 批准号:
2068066 - 财政年份:1993
- 资助金额:
$ 10.64万 - 项目类别:
SELECTIVE TRANSMISSION OF ANTIBODIES TO THE FETUS
选择性地将抗体传递给胎儿
- 批准号:
2068067 - 财政年份:1993
- 资助金额:
$ 10.64万 - 项目类别:
相似国自然基金
半抗原肽/双特异性抗体预定位技术用于实体瘤FAP嵌合抗原受体T细胞治疗的可视化显像研究
- 批准号:
- 批准年份:2021
- 资助金额:55 万元
- 项目类别:面上项目
半抗原肽/双特异性抗体预定位技术用于实体瘤FAP嵌合抗原受体T细胞治疗的可视化显像研究
- 批准号:82171986
- 批准年份:2021
- 资助金额:55.00 万元
- 项目类别:面上项目
T细胞受体样抗体特异性识别乙肝病毒感染细胞的分子机制研究
- 批准号:32000659
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
靶向肿瘤AGR2微环境信号和PD1免疫检查点的双特异抗体对肺部AGR2阳性肿瘤的靶向富集、药理活性及分子机制研究
- 批准号:81872790
- 批准年份:2018
- 资助金额:57.0 万元
- 项目类别:面上项目
靶向肿瘤相关MSC抗体药物的抗肿瘤作用及其机理
- 批准号:81773261
- 批准年份:2017
- 资助金额:61.0 万元
- 项目类别:面上项目
相似海外基金
Advancing Development of Novel Immunotherapy for Chemotherapy-induced Peripheral Neuropathy (CIPN)
推进化疗引起的周围神经病变 (CIPN) 的新型免疫疗法的发展
- 批准号:
10588384 - 财政年份:2023
- 资助金额:
$ 10.64万 - 项目类别:
Engineered Pan-Specific Reagents for N-Glycan Detection and Enrichment
用于 N-聚糖检测和富集的工程泛特异性试剂
- 批准号:
10761111 - 财政年份:2023
- 资助金额:
$ 10.64万 - 项目类别:
Viral vector technology for cell type specific gene delivery
用于细胞类型特异性基因传递的病毒载体技术
- 批准号:
10365787 - 财政年份:2022
- 资助金额:
$ 10.64万 - 项目类别:
Viral vector technology for cell type specific gene delivery
用于细胞类型特异性基因传递的病毒载体技术
- 批准号:
10581499 - 财政年份:2022
- 资助金额:
$ 10.64万 - 项目类别:
A Next-Generation Therapeutic for Treatment of TNFα-mediated Inflammatory Diseases
治疗 TNFα 介导的炎症性疾病的下一代疗法
- 批准号:
10547573 - 财政年份:2022
- 资助金额:
$ 10.64万 - 项目类别: